Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

05-Aug-2010 - Germany

Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec. The milestone reached was the selection of a candidate compound for pre-development studies in an inflammation and immunology programme.

Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: "This is the tenth milestone achieved since the inception of the collaboration between Boehringer Ingelheim and Evotec in 2004, thus underlining the great success of one of the largest and most significant global research alliances between pharma and biotech."

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance